Evista Shortage: What Providers and Prescribers Need to Know in 2026

Patients prescribed Evista (raloxifene hydrochloride) for postmenopausal osteoporosis management or invasive breast cancer risk reduction are increasingly reporting difficulty filling their prescriptions at retail pharmacies. While raloxifene is not formally listed on the FDA's drug shortage database as of 2026, localized supply gaps are prevalent enough to warrant clinical awareness and proactive patient counseling.

Current Supply Status: No FDA-Listed Shortage, But Real Access Problems

As of early 2026, the FDA CDER Drug Shortages database does not list raloxifene as a drug in shortage. Multiple generic manufacturers — including Aurobindo Pharma and others — continue to produce raloxifene 60 mg tablets, and wholesale distribution through major drug distributors remains active.

However, providers should be aware that the absence of an FDA shortage listing does not equate to uniform pharmacy availability. Patients in rural settings, those using independent pharmacies, or those requiring the brand-name Evista (rather than generic raloxifene) are more likely to encounter fill barriers. Patients may present at visits frustrated by repeated denials at their local pharmacy.

Contributing Factors to Local Supply Gaps

Brand discontinuation at retail level. Brand-name Evista (Eli Lilly) is less commonly stocked now that generics dominate the market. Some pharmacies have phased it out of routine inventory.

Demand-based pharmacy ordering. Pharmacies stock based on local demand. Lower-volume prescriptions like raloxifene may be ordered infrequently, leading to gaps between shipments.

Generic manufacturer variability. While multiple manufacturers exist, individual pharmacies source from specific wholesalers who may carry only one manufacturer's product. If that manufacturer has a production pause, local gaps emerge.

Geographic distribution inequities. Supply chains disproportionately serve high-volume urban markets. Rural patients bear a greater burden of localized shortages across many drug classes.

Clinical Implications: What Happens When Patients Miss Doses?

For osteoporosis management, the pharmacokinetics and clinical impact of raloxifene support a relatively forgiving profile for short-term interruptions. Bone mineral density changes occur over months to years, and missing several days of therapy is unlikely to cause a clinically meaningful acute loss. Nonetheless, prolonged interruptions (weeks to months) can erode accumulated benefits.

For patients using raloxifene specifically for invasive breast cancer risk reduction (per NSABP P-2 / STAR trial data), the clinical significance of treatment interruptions is less well-characterized but warrants discussion, particularly for high-risk patients with strong family history or prior atypical ductal hyperplasia.

Therapeutic Alternatives: Clinical Considerations for Switching

If a patient is unable to access raloxifene, the appropriate alternative depends on the primary indication:

Osteoporosis: Bisphosphonates remain first-line per AACE and Endocrine Society guidelines. Alendronate 70 mg once weekly and risedronate are widely available and inexpensive. Denosumab (Prolia) is appropriate for patients who cannot tolerate bisphosphonates or have reduced renal function (eGFR considerations apply). Zoledronic acid (Reclast) is an option for patients preferring annual IV dosing.

Invasive breast cancer risk reduction: Tamoxifen 20 mg daily is an FDA-approved alternative SERM for breast cancer risk reduction and is appropriate in both pre- and postmenopausal women. Notably, raloxifene is preferred over tamoxifen in postmenopausal women due to a more favorable uterine safety profile — raloxifene does not increase endometrial cancer risk, while tamoxifen does carry this risk. Discuss this with patients before switching.

Prescription Recommendations to Reduce Fill Barriers

Providers can take several practical steps to reduce the likelihood of patients facing fill delays:

Write prescriptions for generic raloxifene, not brand Evista, unless there is a specific clinical reason for the brand. Generic is more widely available and significantly less expensive.

Prescribe 90-day supplies whenever possible, and encourage mail-order pharmacy enrollment. This reduces the frequency of fill attempts and maintains consistency.

Allow DAW-0 or DAW-5 to permit pharmacist-selected generic substitution.

Counsel patients proactively to refill 7–10 days before running out, especially if they've encountered fill issues before.

A Tool to Help Your Patients Find Raloxifene in Stock

Recommend medfinder to patients who are struggling to fill their raloxifene prescription. medfinder calls pharmacies near the patient's location to check which ones can fill the prescription, and texts the patient the results. This eliminates the need for patients to spend time on hold with multiple pharmacies and helps them fill their medication faster.

Summary for Providers

No FDA-declared shortage of raloxifene in 2026, but localized pharmacy gaps are common.

Prescribe generic raloxifene and encourage mail-order to minimize access issues.

Short-term interruptions are unlikely to cause acute clinical harm for osteoporosis management, but proactive refill planning is best practice.

For breast cancer risk reduction, discuss the VTE and uterine safety differences between raloxifene and tamoxifen before switching.